Abstract
ProLindac™ (AP5346) is a 25 kDa polymer delivery vehicle based on hydroxypropylmethacrylamide (HPMA) to which DACH (diaminocyclohexane) platinum is bound. DACH platinum is the active moiety in the approved chemotherapeutic, oxaliplatin. The AP5346 polymer prodrug is currently in phase II clinical development. The polymer targets the drug to tumors and a pH-sensitive linker releases platinum more rapidly in low pH environments, as found typically in many tumors. ProLindac has completed a Phase I study in solid tumor cancer patients and has recently completed a Phase I/II monotherapy study in patients with recurrent ovarian cancer. With promising efficacy and safety data from these studies, clinical studies of ProLindac used in combination with other chemotherapeutic agents, including paclitaxel, are planned.
Keywords: HPMA polymer, DACH platinum, AP5346, ProLindac, recurrent ovarian cancer, tumor targeting, clinical trials, chemotherapeutic agents, anticancer, third generation polymer platinum prodrug
Current Bioactive Compounds
Title: AP5346 (ProLindac™), A DACH Platinum Polymer Conjugate in Phase II Trials Against Ovarian Cancer
Volume: 7 Issue: 1
Author(s): David P. Nowotnik
Affiliation:
Keywords: HPMA polymer, DACH platinum, AP5346, ProLindac, recurrent ovarian cancer, tumor targeting, clinical trials, chemotherapeutic agents, anticancer, third generation polymer platinum prodrug
Abstract: ProLindac™ (AP5346) is a 25 kDa polymer delivery vehicle based on hydroxypropylmethacrylamide (HPMA) to which DACH (diaminocyclohexane) platinum is bound. DACH platinum is the active moiety in the approved chemotherapeutic, oxaliplatin. The AP5346 polymer prodrug is currently in phase II clinical development. The polymer targets the drug to tumors and a pH-sensitive linker releases platinum more rapidly in low pH environments, as found typically in many tumors. ProLindac has completed a Phase I study in solid tumor cancer patients and has recently completed a Phase I/II monotherapy study in patients with recurrent ovarian cancer. With promising efficacy and safety data from these studies, clinical studies of ProLindac used in combination with other chemotherapeutic agents, including paclitaxel, are planned.
Export Options
About this article
Cite this article as:
P. Nowotnik David, AP5346 (ProLindac™), A DACH Platinum Polymer Conjugate in Phase II Trials Against Ovarian Cancer, Current Bioactive Compounds 2011; 7 (1) . https://dx.doi.org/10.2174/157340711795163794
DOI https://dx.doi.org/10.2174/157340711795163794 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proteomic Analysis of Mitochondrial Proteins on the Mechanism of Apoptotic Under Amorphophallus konjac Tuber (KONJAC) Extracts in Gas tric Cancer Cell
Current Proteomics Antitumor Properties of Natural Compounds and Related Molecules
Recent Patents on Anti-Cancer Drug Discovery Design and Synthesis of Novel Schiff Base-Benzothiazole Hybrids as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Insights into Targeting Colon Cancer Cell Fate at the Level of Proteoglycans / Glycosaminoglycans
Current Medicinal Chemistry Recent Advances in Therapeutic Peptides for Breast Cancer Treatment
Current Protein & Peptide Science Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry The Epigenetic Origin of Aneuploidy
Current Genomics Structural Basis for Binding of Aurora-A<sup>G198N</sup>- INCENP Complex: MD Simulations and Free Energy Calculations
Protein & Peptide Letters The potential for circulating microRNAs in the diagnosis of myocardial infarction: a novel approach to disease diagnosis and treatment
Current Pharmaceutical Design Primary Tumors of the Sacrum: Imaging Findings
Current Medical Imaging Systematic Analysis of RNAi Reports Identifies Dismal Commonality at Gene-Level and Reveals an Unprecedented Enrichment in Pooled shRNA Screens
Combinatorial Chemistry & High Throughput Screening Enzyme Inhibition as a Key Target for the Development of Novel Metal-Based Anti-Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Tissue Distribution and Pharmacodynamics: A Complicated Relationship
Current Drug Metabolism Enrichment of Up-regulated and Down-regulated Gene Clusters Using Gene Ontology, miRNAs and lncRNAs in Colorectal Cancer
Combinatorial Chemistry & High Throughput Screening Repair and Translesion DNA Polymerases as Anticancer Drug Targets
Anti-Cancer Agents in Medicinal Chemistry Recent Patents in Toll-like Receptor Pathways and Relevance to Cancer
Recent Patents on Anti-Cancer Drug Discovery Modulation of Photosensitization Processes for an Improved Targeted Photodynamic Therapy
Current Medicinal Chemistry Modulation of Cellular Function by TAT Mediated Transduction of Full Length Proteins
Current Protein & Peptide Science Role of Farletuzumab in Epithelial Ovarian Carcinoma
Current Pharmaceutical Design Combination Therapy of Cisplatin and other Agents for Osteosarcoma: A Review
Current Cancer Therapy Reviews